Search  in | Advanced
   Print  

Umbilical Cord Blood

Umbilical cord blood (UCB), once regarded as biological waste, has become an accepted source of hematopoietic stem cells/hematopoietic progenitor cells (HSCs/HPCs). UCB can be safely collected by obstetricians following delivery of the baby; it can also be collected by dedicated collection staff. In either setting, UCB is collected into a plastic blood bag (similar to the procedure at a blood drive) and usually measures up to one cup.  The unit then undergoes further processing (primarily to remove red blood cells) and cryopreservation (freezing) and is stored in a liquid nitrogen freezer at less than -135ºC (-211ºF) for eventual use. UCB can be stored in a private bank for potential use by a family member or in a public bank for anyone in the community (i.e., an unrelated recipient). 

UCB has several advantages as a source of HSCs/HPCs.  Because the HPCs in cord blood may be less mature, it is accepted that fewer HPCs are required from UCB than from marrow and peripheral blood. Use of UCB for HPC transplantation offers other benefits, such as decreased incidence of graft-versus-host disease (a complication of transplantation that can be life-threatening); reduced HLA matching requirements (i.e., a lower level match may be acceptable); and decreased search time, since units are banked and already HLA-typed. Patients with rare HLA types are often successful in finding a suitable cord graft when other sources are not acceptable.



Quick Links:

Umbilical Cord Blood Donation FAQs



Back

Last modified on 8/8/2006 12:02:47 PM
What's New!
2008 AABB Annual Meeting & TXPO Online
Details
AABB Weekly Report - October 3, 2008
Details
AABB Announces 2008 Award and Scholarship Recipients
Details
Latest Developments to be Highlighted at AABB Annual Meeting and TXPO in October
Details
The National Blood Foundation (NBF) Announces Recipients of the 2008 NBF Scientific Research Grants
Details
Association Bulletin #08-04 - Strategies to Reduce Adverse Reactions and Injuries in Younger Donors
Details
Summary of Draft Comments to be Submitted to TJC on Blood Management Performance Measures
Details
Significant Changes to the Standards for Cellular Therapy Product Services, 3rd edition
Details
First Ever National Biovigilance Network in the U.S. Reaches $1 Million in Funding, Prepares for Fall Pilot Launch
Details
2008 West Nile Virus Biovigilance Network
Details
List of AABB-Accredited Facilities with Approved Variances for ISBT 128
Details
Instructions on Applying for an AABB Variance
Details